ARGENX (ARGX) Company Report

Analyst Coverage

Research analysts who have asked questions during ARGENX earnings calls.

Derek Archila

Wells Fargo

8 questions for ARGX

Also covers: APLS, ARVN, ASND +11 more

Rajan Sharma

Goldman Sachs Group, Inc.

8 questions for ARGX

Also covers: AUTL, AZN, CVAC +6 more

Samantha Semenkow

Citigroup Inc.

8 questions for ARGX

Also covers: AGIO, ALLO, BEAM +10 more

Tazeen Ahmad

Bank of America

8 questions for ARGX

Also covers: ACAD, ALNY, APLS +22 more

Douglas Tsao

H.C. Wainwright & Co.

7 questions for ARGX

Also covers: ALKS, APLS, ARQT +21 more

Victor Floch

BNP Paribas

7 questions for ARGX

Also covers: GMAB

Yaron Werber

TD Cowen

7 questions for ARGX

Also covers: ALEC, AMGN, ASND +15 more

Yatin Suneja

Guggenheim Partners

7 questions for ARGX

Also covers: ACAD, AXSM, CLDX +11 more

Thomas Smith

Leerink Partners

6 questions for ARGX

Also covers: ACRS, CLDX, CNTB +7 more

Alex Thompson

Stifel Financial Corp.

5 questions for ARGX

Also covers: ASND, CRNX, IMVT +3 more

Danielle Brill

Truist Securities

5 questions for ARGX

Also covers: ACAD, BBIO, BIIB +6 more

James Gordon

JPMorgan Chase & Co.

5 questions for ARGX

Also covers: AZN, GMAB, GRFS +4 more

Suzanne van Voorthuizen

Kempen & Co

5 questions for ARGX

Also covers: BNTX, GMAB, HOOK +3 more

Akash Tewari

Jefferies

4 questions for ARGX

Also covers: ALKS, APLS, ARVN +15 more

Amy Li

Jefferies Financial Group Inc.

4 questions for ARGX

Also covers: IRWD, JAZZ, MDGL

Gavin Clark-Gartner

Evercore ISI

4 questions for ARGX

Also covers: ACRS, ASND, CMPS +12 more

Matthew Phipps

William Blair

4 questions for ARGX

Also covers: ABBV, AGEN, AMGN +8 more

Myles Minter

William Blair & Company

4 questions for ARGX

Also covers: ALEC, ALNY, ARCT +12 more

Xian Deng

Berenberg

4 questions for ARGX

Also covers: GLPG, GMAB

Alexander Thompson

Stifel

3 questions for ARGX

Also covers: ACRS, ASND, CRNX +5 more

Andy Chen

Wolfe Research, LLC

3 questions for ARGX

Also covers: CRNX, IMVT, INCY +7 more

Charles Pitman-King

Barclays

3 questions for ARGX

Also covers: GRFS

Joel Beatty

Baird

3 questions for ARGX

Also covers: ACAD, ALKS, AMLX +11 more

Morgan

Morgan Stanley

3 questions for ARGX

Also covers: SDGR

Vikram Purohit

Morgan Stanley

3 questions for ARGX

Also covers: ABSI, ARQT, ASND +11 more

Allison Bratzel

Piper Sandler Companies

2 questions for ARGX

Also covers: ABCL, AKBA, ALXO +7 more

Cassie Yuan

RBC Capital Markets

2 questions for ARGX

Jacob Mekhael

KBC Securities

2 questions for ARGX

Also covers: AUTL, GLPG

Justin Smith

Bernstein

2 questions for ARGX

Also covers: AZN, GRF, GSK +1 more

Leland Gershell

Oppenheimer & Co. Inc.

2 questions for ARGX

Also covers: ASND, CAPR, CASI +13 more

Luca Issi

RBC Capital Markets

2 questions for ARGX

Also covers: ADVM, ALLO, ALNY +13 more

Manos Mastorakis

Deutsche Bank

2 questions for ARGX

Also covers: BNTX, GLPG

Nick

Virtue Capital

2 questions for ARGX

Also covers: ARE, FRST, IOVA +1 more

Richard Vosser

JPMorgan Chase & Co.

2 questions for ARGX

Also covers: AZN, MOLN, NVO +2 more

Sophia Graeff Buhl-Nielsen

JPMorgan Chase & Co.

2 questions for ARGX

Brian Conley

Leerink Partners

1 question for ARGX

Charles Pitman

Barclays PLC

1 question for ARGX

Also covers: GRFS, SOAGY

David Nierengarten

Wedbush Securities

1 question for ARGX

Also covers: ITOS, KNSA, NUVB +4 more

Maddalena Delma Caiati

Guggenheim

1 question for ARGX

Mehdi Goudarzi

Truist Securities

1 question for ARGX

Also covers: EDIT, NTLA, RARE +1 more

Morgan on for Sean Laaman

Morgan Stanley

1 question for ARGX

Nat Charoensook

Leerink Partners

1 question for ARGX

Also covers: IMUX, VKTX

Sean Laaman

Morgan Stanley & Co.

1 question for ARGX

Also covers: ACAD, AXSM, BGNE +8 more

Tyler Van Buren

TD Cowen

1 question for ARGX

Also covers: ADVM, ALLO, ARQT +13 more

Viktor Dziuba

BNP Paribas

1 question for ARGX

Latest news

Recent press releases and 8-K filings for ARGX.

ARGENX SE Reports Strong Full Year 2025 Financial Results and Pipeline Progress

ARGX

Earnings

Product Launch

New Projects/Investments

ARGENX SE reported $4.2 billion in global product net sales for the full year 2025, representing 90% year-over-year growth, and achieved its first year of operating profitability with $1.1 billion in operating income.
The company's lead product, VYVGART, reached 19,000 patients globally and achieved Blockbuster Status as of Q3 2025.
A PDUFA target action date of May 10, 2026, is set for the seronegative gMG label expansion, supported by positive ADAPT SERON and OCULUS results, with the latter also supporting a planned sBLA submission for ocular myasthenia gravis.
By the end of 2026, ARGENX SE expects its pipeline to include four Phase 3 molecules and a total of 10 molecules in clinical development, with several registrational readouts anticipated over the next 24 months.

1 day ago

6-K

Argenx Reports Strong FY 2025 Financial Results and Positive Ocular MG Phase 3 Data

ARGX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Argenx reported $4.2 billion in product net sales for the full year 2025, representing 90% year-over-year growth, and achieved its first year of annual operating profitability with $1.1 billion in operating profit for the year.
The company announced positive Phase 3 ADAPT OCULUS study results for VYVGART in ocular myasthenia gravis, meeting its primary endpoint with a statistically significant improvement (p-value of 0.012), and plans to file an sBLA with the FDA.
VYVGART reached 19,000 patients globally by the end of 2025, driven in part by the successful launch of its prefilled syringe, and anticipates further label expansions for seronegative MG (PDUFA date May tenth) and ocular MG.
Argenx ended Q4 2025 with a strong cash balance of $4.4 billion and expects total operating expenses in 2026 to grow at a similar rate as 2025, with most growth in R&D.

1 day ago

Transcript

ARGENX Reports Strong Full-Year 2025 Financial Results and Positive Phase 3 Ocular MG Data

ARGX

Earnings

Product Launch

CEO Change

ARGENX reported Q4 2025 product net sales of $1.3 billion and full-year 2025 product net sales of $4.2 billion, marking 90% year-over-year growth and the company's first year of annual operating profitability with $1.1 billion in operating profit.
The company announced positive results from its Phase 3 ADAPT OCULUS study, showing statistically significant improvement for VYVGART in ocular myasthenia gravis (p-value of 0.012), and plans to file an sBLA with the FDA.
VYVGART reached 19,000 patients globally by the end of 2025 , with anticipated label expansions for seronegative MG (PDUFA date May 10th) and ocular MG expected to add 11,000 and 7,000 eligible patients, respectively.
Karen Massey will transition from COO to CEO, succeeding Tim Van Hauwermeiren.

1 day ago

Transcript

ARGENX Reports Q4 2025 Results, Announces Positive Ocular MG Trial Data, and Provides 2026 Outlook

ARGX

Product Launch

Guidance Update

New Projects/Investments

argenx concluded 2025 with approximately 19,000 patients globally on treatment with VYVGART, with the successful launch of the prefilled syringe contributing to this growth.
The company announced positive Phase III ADAPT-OCULUS results for VYVGART in ocular myasthenia gravis (MG), demonstrating a statistically significant improvement (p-value of 0.012) and paving the way for potential label expansion to an additional 7,000 patients in the U.S..
argenx anticipates a PDUFA date of May 10th for seronegative MG, which is expected to expand the addressable market by 11,000 patients, and projects that it will take approximately two quarters after approval for payer policies to be established for new indications.
Combined R&D and SG&A expenses are forecasted to grow at a similar rate in 2026 as in 2025 (which saw a 30% increase over 2024), with the majority of this growth allocated to R&D to support the company's pipeline.

1 day ago

Transcript

ARGENX SE Announces Positive Phase 3 Trial Results for VYVGART in Ocular Myasthenia Gravis

ARGX

Product Launch

New Projects/Investments

ARGENX SE announced positive topline results from its Phase 3 ADAPT OCULUS trial for VYVGART in ocular myasthenia gravis (oMG), meeting its primary endpoint with a p-value of 0.012.
Patients treated with VYVGART demonstrated a 4.04 point improvement in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4, compared to a 1.99 point improvement in the placebo group.
VYVGART was well tolerated and had a favorable safety profile in oMG patients, consistent with prior studies, with no new safety concerns identified.
These results support a planned Supplemental Biologics License Application (sBLA) submission to the U.S. FDA to expand VYVGART's label into oMG, which the company expects to submit by the end of the third quarter 2026.

1 day ago

6-K

ARGENX Announces FDA Acceptance of Priority Review for VYVGART in Seronegative gMG

ARGX

Product Launch

New Projects/Investments

ARGENX SE announced on January 13, 2026, that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART (efgartigimod alfa-fcab).
The sBLA is for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG).
The PDUFA target action date for the FDA's decision is May 10, 2026.
This application is supported by data from the Phase 3 ADAPT SERON study, which met its primary endpoint, demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo.

Jan 13, 2026, 11:05 AM

6-K

argenx Reports Preliminary Q4 and Full-Year 2025 Results, Outlines 2026 Strategic Priorities, and Announces Leadership Changes

ARGX

Earnings

Guidance Update

Management Change

argenx reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting 90% year-over-year growth, with $1.29 billion in fourth-quarter sales.
The company anticipates four registrational readouts in 2026, including the first for empasiprubart, and expects to launch AChR-Ab seronegative gMG by the end of 2026 if approved.
By the end of 2026, argenx expects to have a total of 10 clinical-stage molecules in its pipeline, with three new molecules entering Phase 1 studies during the year.
Karen Massey is set to transition from Chief Operating Officer to Chief Executive Officer and Executive Director, while current CEO Tim Van Hauwermeiren will become non-Executive Director and Chairman of the Board, subject to shareholder approval on May 6, 2026.

Jan 12, 2026, 9:05 PM

6-K

argenx Reports Strong Q4 2025 VYVGART Sales and Pipeline Progress

ARGX

Earnings

Product Launch

New Projects/Investments

argenx reported strong financial performance for Q4 2025, with VYVGART sales reaching approximately $1.3 billion, representing a 14% increase from the previous quarter. The company almost doubled its business in 2025 compared to 2024 and achieved structural profitability in 2025.
The company is actively expanding VYVGART's market, with a supplemental Biologics License Application (sBLA) submitted for seronegative Myasthenia Gravis (MG), targeting potential approval and launch in the second half of 2026. Additionally, ocular MG data is anticipated in Q1 2026.
argenx is advancing a robust pipeline, with 10 molecules in clinical development and four in Phase III. Key upcoming data readouts include autoimmune myositis in Q3 2026, ITP in Q4 2026, and EMPA in MMN in Q4 2026.
The company plans to continue increasing its R&D investment to fully develop its growing late-stage and early-stage pipeline, aligning with its strategic agenda as a growth and innovation company.

Jan 12, 2026, 4:15 PM

Transcript

argenx Highlights Strong VYVGART Growth and Pipeline Progress at J.P. Morgan Healthcare Conference

ARGX

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

argenx reported Q4 2025 VYVGART sales of $1.3 billion, a 14% increase from the previous quarter, nearly doubling its business in 2025 compared to 2024, and achieving structural profitability in 2025.
The company is on track to impact 50,000 patients by 2030 through 10 labeled indications and aims to have five new molecules in Phase 3 by 2030. Currently, 19,000 patients are on VYVGART, and 10 registration trials are running in 2026.
Key upcoming data readouts for efgartigimod include ocular MG in Q1 2026, myositis in Q3 2026, and ITP in Q4 2026. The sBLA for seronegative MG patients was submitted, with potential approval in H2 2026.
VYVGART achieved blockbuster status in CIDP in Q3 2025 and is the number one prescribed biologic in MG, driving 60% of biologic growth in that indication. The company plans to continue expanding the market for VYVGART in MG and CIDP, with new indications like autoimmune myositis and Sjögren's disease.
argenx is advancing its pipeline with 10 molecules in clinical development, including four in Phase 3, and is developing next-gen FcRn molecules like ARGX-213 and ARGX-124, as well as new molecules through partnerships. The company expects its investment in R&D to continue to increase as it advances its pipeline.

Jan 12, 2026, 4:15 PM

Transcript

argenx Reports Strong 2025 Performance and Outlines 2026 Strategic Priorities at J.P. Morgan Healthcare Conference

ARGX

Earnings

Guidance Update

New Projects/Investments

argenx reported strong 2025 financial results, with VYVGART sales reaching $1.3 billion in Q4 2025, a 14% increase quarter-over-quarter, and the business nearly doubling in 2025 compared to 2024. The company also achieved structural profitability in 2025.
The company is advancing towards its Vision 2030 goal of impacting 50,000 patients across 10 labeled indications and having five new molecules in Phase 3, with 19,000 patients currently on VYVGART and 10 registration trials underway in 2026.
Significant upcoming data readouts include efgartigimod for Ocular MG in Q1 2026, Myositis in Q3 2026, and ITP in Q4 2026. Empasiprubart (empa) is expected to have MMN data in Q4 2026. The company anticipates increased R&D investment to support its expanding pipeline.